Cargando…
Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and contin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918525/ https://www.ncbi.nlm.nih.gov/pubmed/35295840 http://dx.doi.org/10.3389/fneur.2022.788427 |
_version_ | 1784668746576560128 |
---|---|
author | Fröhlich, Holger Bontridder, Noémi Petrovska-Delacréta, Dijana Glaab, Enrico Kluge, Felix Yacoubi, Mounim El Marín Valero, Mayca Corvol, Jean-Christophe Eskofier, Bjoern Van Gyseghem, Jean-Marc Lehericy, Stepháne Winkler, Jürgen Klucken, Jochen |
author_facet | Fröhlich, Holger Bontridder, Noémi Petrovska-Delacréta, Dijana Glaab, Enrico Kluge, Felix Yacoubi, Mounim El Marín Valero, Mayca Corvol, Jean-Christophe Eskofier, Bjoern Van Gyseghem, Jean-Marc Lehericy, Stepháne Winkler, Jürgen Klucken, Jochen |
author_sort | Fröhlich, Holger |
collection | PubMed |
description | Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and continuous monitoring of disease symptoms, also outside clinics. This includes the possibility to continuously and sensitively monitor the response to treatment, hence opening the opportunity to adapt medication pathways quickly. In addition, DMs may in the future allow early diagnosis, stratification of patient subgroups and prediction of clinical outcomes. Thus, DMs could complement or in certain cases even replace classical examiner-based outcome measures and molecular biomarkers measured in cerebral spinal fluid, blood, urine, saliva, or other body liquids. Altogether, DMs could play a prominent role in the emerging field of precision medicine. However, realizing this vision requires dedicated research. First, advanced data analytical methods need to be developed and applied, which extract candidate DMs from raw signals. Second, these candidate DMs need to be validated by (a) showing their correlation to established clinical outcome measures, and (b) demonstrating their diagnostic and/or prognostic value compared to established biomarkers. These points again require the use of advanced data analytical methods, including machine learning. In addition, the arising ethical, legal and social questions associated with the collection and processing of sensitive patient data and the use of machine learning methods to analyze these data for better individualized treatment of the disease, must be considered thoroughly. Using Parkinson's Disease (PD) as a prime example of a complex multifactorial disorder, the purpose of this article is to critically review the current state of research regarding the use of DMs, discuss open challenges and highlight emerging new directions. |
format | Online Article Text |
id | pubmed-8918525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89185252022-03-15 Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease Fröhlich, Holger Bontridder, Noémi Petrovska-Delacréta, Dijana Glaab, Enrico Kluge, Felix Yacoubi, Mounim El Marín Valero, Mayca Corvol, Jean-Christophe Eskofier, Bjoern Van Gyseghem, Jean-Marc Lehericy, Stepháne Winkler, Jürgen Klucken, Jochen Front Neurol Neurology Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and continuous monitoring of disease symptoms, also outside clinics. This includes the possibility to continuously and sensitively monitor the response to treatment, hence opening the opportunity to adapt medication pathways quickly. In addition, DMs may in the future allow early diagnosis, stratification of patient subgroups and prediction of clinical outcomes. Thus, DMs could complement or in certain cases even replace classical examiner-based outcome measures and molecular biomarkers measured in cerebral spinal fluid, blood, urine, saliva, or other body liquids. Altogether, DMs could play a prominent role in the emerging field of precision medicine. However, realizing this vision requires dedicated research. First, advanced data analytical methods need to be developed and applied, which extract candidate DMs from raw signals. Second, these candidate DMs need to be validated by (a) showing their correlation to established clinical outcome measures, and (b) demonstrating their diagnostic and/or prognostic value compared to established biomarkers. These points again require the use of advanced data analytical methods, including machine learning. In addition, the arising ethical, legal and social questions associated with the collection and processing of sensitive patient data and the use of machine learning methods to analyze these data for better individualized treatment of the disease, must be considered thoroughly. Using Parkinson's Disease (PD) as a prime example of a complex multifactorial disorder, the purpose of this article is to critically review the current state of research regarding the use of DMs, discuss open challenges and highlight emerging new directions. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8918525/ /pubmed/35295840 http://dx.doi.org/10.3389/fneur.2022.788427 Text en Copyright © 2022 Fröhlich, Bontridder, Petrovska-Delacréta, Glaab, Kluge, Yacoubi, Marín Valero, Corvol, Eskofier, Van Gyseghem, Lehericy, Winkler and Klucken. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Fröhlich, Holger Bontridder, Noémi Petrovska-Delacréta, Dijana Glaab, Enrico Kluge, Felix Yacoubi, Mounim El Marín Valero, Mayca Corvol, Jean-Christophe Eskofier, Bjoern Van Gyseghem, Jean-Marc Lehericy, Stepháne Winkler, Jürgen Klucken, Jochen Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease |
title | Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease |
title_full | Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease |
title_fullStr | Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease |
title_full_unstemmed | Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease |
title_short | Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease |
title_sort | leveraging the potential of digital technology for better individualized treatment of parkinson's disease |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918525/ https://www.ncbi.nlm.nih.gov/pubmed/35295840 http://dx.doi.org/10.3389/fneur.2022.788427 |
work_keys_str_mv | AT frohlichholger leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT bontriddernoemi leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT petrovskadelacretadijana leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT glaabenrico leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT klugefelix leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT yacoubimounimel leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT marinvaleromayca leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT corvoljeanchristophe leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT eskofierbjoern leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT vangyseghemjeanmarc leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT lehericystephane leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT winklerjurgen leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease AT kluckenjochen leveragingthepotentialofdigitaltechnologyforbetterindividualizedtreatmentofparkinsonsdisease |